ONCO

Onconetix, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.74
52-Week Range: $0.59 – $209.50
Market Cap: $3.21M
P/E (TTM): 0.00
EPS (TTM): 310.39
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.21
PEG Ratio: —
Return on Equity: -105.23%
Return on Assets: -27.03%
Gross Margin: 80.40%
Operating Margin: -13112.09%
Profit Margin: 0.00%
Current Ratio: 2.21
Debt/Equity: 0.01
Total Debt: $187.13K
Free Cash Flow: $-5.92M
Revenue Growth: -83.90%
Earnings Growth: —
Enterprise Value: $-2.86M

ONCO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$58.47K	$2.52M	$815.37K
Cost of Revenue	$0.00	$1.19M	$1.47M	$182.46K
Gross Profit	$0.00	-$1.13M	$1.06M	$632.91K
Research & Development	$4.13M	$1.95M	$154.36K	-$66.13K
Selling, General & Admin	$9.35M	$14.77M	$11.23M	$7.04M
Operating Expenses	$13.48M	$16.72M	$11.39M	$6.98M
Operating Income	-$13.48M	-$17.85M	-$10.33M	-$6.34M
EBITDA	-$13.41M	-$36.71M	-$57.60M	-$13.27M
Pretax Income	-$13.42M	-$37.42M	-$59.74M	-$14.03M
Income Tax	$0.00	-$12.59K	-$1.05M	$525.00
Net Income	-$13.42M	-$37.41M	-$58.69M	-$14.03M
Diluted EPS	-151867.29	-285570.18	-21301.06	-828.00
Diluted Shares	89	131	2765	18753

ONCO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$25.75M	$4.55M	$646.50K	$5.22M
Receivables	$35.85K	$149.73K	$96.31K	$388.87K
Inventory	$0.00	$364.05K	$64.08K	$149.96K
Current Assets	$26.26M	$5.84M	$950.27K	$6.07M
Total Assets	$26.31M	$87.52M	$28.18M	$24.93M
Current Liabilities	$3.92M	$17.19M	$18.29M	$9.14M
Long-Term Debt	—	$118.86K	—	—
Total Debt	$0.00	$9.89M	$9.45M	$48.77K
Total Liabilities	$3.92M	$86.11M	$18.57M	$9.16M
Retained Earnings	-$19.38M	-$56.79M	-$115.68M	-$131.21M
Shareholders' Equity	$22.39M	-$5.60M	$9.61M	$15.77M
Working Capital	$22.34M	-$11.35M	-$17.34M	-$3.07M
Net Debt	—	$5.18M	$8.68M	—

ONCO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.68M	-$13.58M	-$10.50M	-$9.68M
Capital Expenditure	-$9.34K	-$55.04K	-$28.47K	—
Free Cash Flow	-$8.68M	-$13.64M	-$10.52M	-$9.68M
Depreciation & Amortisation	$6.75K	$43.94K	$731.35K	$15.17K
Stock-Based Compensation	$1.97M	$329.76K	$438.65K	$74.27K
Investing Cash Flow	-$32.66K	-$8.65M	-$28.47K	$0.00
Financing Cash Flow	$32.53M	$1.04M	$6.74M	$14.45M
Share Repurchases	-$566.81K	-$58.98K	-$718.00	-$1.71M
Net Change in Cash	$23.82M	-$21.19M	-$3.78M	$4.77M

ONCO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$101.63K	$106.49K	$303.65K	$303.60K	$21.46K	$17.12K
Cost of Revenue	$55.80K	$35.99K	$34.76K	$55.91K	$23.11K	$12.82K
Gross Profit	$45.83K	$70.50K	$268.89K	$247.68K	-$1.66K	$4.30K
Research & Development	$24.45K	-$111.67K	-$3.21K	$24.29K	$50.82K	$3.44K
Selling, General & Admin	$1.67M	$1.52M	$2.34M	$1.50M	$2.04M	$2.25M
Operating Expenses	$1.70M	$1.41M	$2.34M	$1.53M	$2.09M	$2.25M
Operating Income	-$1.65M	-$1.34M	-$2.07M	-$1.28M	-$2.09M	-$2.24M
EBITDA	-$8.32M	-$2.15M	-$8.48M	$5.68M	-$4.21M	-$2.86M
Pretax Income	-$8.55M	-$2.37M	-$8.78M	$5.67M	-$4.21M	-$2.87M
Income Tax	$0.00	$0.00	$0.00	$525.00	$0.00	—
Net Income	-$8.55M	-$2.37M	-$8.78M	$5.67M	-$4.21M	-$2.87M
Diluted EPS	-2272.50	-237.91	-312.50	—	-67.10	-1.28
Diluted Shares	4275	11353	28109	—	62852	2.24M

ONCO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.58M	$283.51K	$836.56K	$5.22M	$3.72M	$5.94M
Receivables	$67.66K	$61.17K	$42.80K	$388.87K	$100.06K	$48.74K
Inventory	$155.66K	$153.07K	$151.56K	$149.96K	$137.64K	$210.45K
Current Assets	$2.42M	$930.53K	$1.30M	$6.07M	$4.33M	$6.52M
Total Assets	$18.78M	$19.12M	$19.68M	$24.93M	$14.83M	$16.43M
Current Liabilities	$14.04M	$12.69M	$16.30M	$9.14M	$3.07M	$2.94M
Total Debt	$9.05M	$8.75M	$166.42K	$48.77K	$289.92K	$187.13K
Total Liabilities	$14.26M	$13.21M	$16.30M	$9.16M	$3.08M	$2.96M
Retained Earnings	-$125.40M	-$128.10M	-$136.88M	-$131.21M	-$135.43M	-$138.30M
Shareholders' Equity	$4.52M	$5.91M	$3.38M	$15.77M	$11.75M	$13.47M
Working Capital	-$11.62M	-$11.76M	-$15.00M	-$3.07M	$1.26M	$3.57M
Net Debt	$7.38M	$8.45M	—	—	—	—

ONCO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.00M	-$1.41M	-$3.18M	-$3.09M	-$2.12M	-$1.92M
Free Cash Flow	-$2.00M	-$1.41M	-$3.18M	-$3.09M	-$2.12M	-$1.92M
Depreciation & Amortisation	$4.75K	$3.70K	$3.39K	$3.34K	$5.40K	$2.63K
Stock-Based Compensation	$29.26K	$30.98K	$9.79K	$4.23K	$22.30K	$7.36K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$2.87M	$744.57K	$4.29M	$6.55M	$631.79K	$4.17M
Share Repurchases	-$1.32M	-$395.68K	$0.00	$0.00	-$250.00	-$98.00
Net Change in Cash	$870.57K	-$665.72K	$1.11M	$3.46M	-$1.49M	$2.25M

Market Snapshot

About

Onconetix, Inc. develops oncology therapeutics focused on novel cancer treatments. The company works on targeted therapies and innovative drug candidates for various cancer types.